Consequently, the combination of low levels of 3βAdiol (a weaker androgen metabolite) and increased CYP7B1 expression, along with a decreased expression of ERβ, is unfavorable and likely to play a significant role in the initial stages of prostate cancer development [9]. Here, ESR2 is linked to prostate carcinoma.